Dube Geoffrey K, Cohen David J
Columbia University College of Physicians and Surgeons, New York, NY 10032 USA.
Curr Opin Nephrol Hypertens. 2007 Nov;16(6):547-53. doi: 10.1097/MNH.0b013e3282f1191e.
The Model for End-Stage Liver Disease (MELD) scoring system for prioritizing patients for liver transplantation heavily weights serum creatinine, leading to increased numbers of liver transplant patients with renal insufficiency receiving both liver-alone transplants and liver-kidney transplants. With available organs being scarce, review of recent outcomes and guidelines for their use is timely.
Despite lower average renal function in liver transplant recipients in the era of Model for End-Stage Liver Disease scoring, and poor renal function predicting inferior outcomes, overall outcomes are unchanged. Combined liver-kidney transplants have increased three-fold. Despite inferior short-term kidney and liver-graft survival rates, long-term success rates are equivalent to single-organ transplantation. Only patients requiring dialysis at the time of transplantation clearly benefit from combined liver-kidney transplants. Waitlisted patients with nonresolving severe acute kidney injury for 6-8 weeks or substantial irreversible renal parenchymal damage are also deemed appropriate candidates. Many combined liver-kidney recipients have lesser degrees of renal dysfunction, however. Accurate determination of renal function in patients with cirrhosis remains problematic.
Appropriate patients with irreversible end-stage renal and liver disease clearly deserve combined liver-kidney transplants. More data on the reliable assessment of renal function, renal pathology, and outcomes are needed, however.
终末期肝病模型(MELD)评分系统用于对肝移植患者进行优先排序,该系统高度重视血清肌酐,导致肾功能不全的肝移植患者接受单纯肝移植和肝肾联合移植的人数增加。鉴于可用器官稀缺,及时回顾近期疗效及使用指南很有必要。
尽管在终末期肝病模型评分时代,肝移植受者的平均肾功能较低,且肾功能差预示着预后不良,但总体疗效并无变化。肝肾联合移植增加了两倍。尽管肝肾联合移植的短期肾脏和肝脏移植存活率较低,但长期成功率与单器官移植相当。只有在移植时需要透析的患者显然能从肝肾联合移植中获益。等待名单上患有持续6 - 8周未缓解的严重急性肾损伤或有大量不可逆肾实质损伤的患者也被视为合适的候选者。然而,许多肝肾联合移植受者的肾功能不全程度较轻。准确测定肝硬化患者的肾功能仍然存在问题。
患有不可逆终末期肾和肝病的合适患者显然值得接受肝肾联合移植。然而,还需要更多关于肾功能可靠评估、肾脏病理学和疗效的数据。